The relationship between composite dietary antioxidant index and odds of depression: A systematic review and dose-response meta-analysis of observational studies.

J Affect DisordJul 21, 2026 (epub)
Clinical ResearchPsychiatry

Hamid Ahmadirad, Yahya Pasdar, Milad Mohammadzadeh et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined the relationship between the composite dietary antioxidant index (CDAI) and depression odds across four observational studies. The analysis found that higher CDAI scores were associated with lower odds of depression, with an odds ratio of 0.62 (95% CI: 0.51-0.76).

Key findings

  • Higher CDAI scores were associated with lower odds of depression (OR: 0.62; 95% CI: 0.51-0.76).
  • The exploratory linear dose-response analysis showed no significant association for a one-unit increase in CDAI score (OR: 0.96; 95% CI: 0.91-1.02).
  • Substantial heterogeneity was noted in the studies included (I² = 48.5% for the main analysis).

Why it matters

Understanding the relationship between dietary patterns and mental health can inform dietary recommendations and interventions aimed at reducing depression risk. Antioxidant-rich diets may play a role in mental well-being.

What to keep in mind

The study included a limited number of observational studies and exhibited substantial heterogeneity.

Source

PubMed · PMID 42480721

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.